We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
J&J Unit Halts Development of Fulranumab; Returns Rights to Amgen Pfizer’s Bococizumab Shines in Second Phase 3 Lipid-Reducing Trial Taiho’s Colorectal Cancer Candidate Meets Primary Endpoints Regeneron/Sanofi’s Dupilumab Meets Primary Endpoints